Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

손익 계산서 
분기별 데이터

Gilead Sciences Inc., 연결 손익 계산서(Quarterly Data)

US$ 단위: 백만 달러

Microsoft Excel
3개월 종료 2026. 3. 31. 2025. 12. 31. 2025. 9. 30. 2025. 6. 30. 2025. 3. 31. 2024. 12. 31. 2024. 9. 30. 2024. 6. 30. 2024. 3. 31. 2023. 12. 31. 2023. 9. 30. 2023. 6. 30. 2023. 3. 31. 2022. 12. 31. 2022. 9. 30. 2022. 6. 30. 2022. 3. 31. 2021. 12. 31. 2021. 9. 30. 2021. 6. 30. 2021. 3. 31.
물품 판매 6,946 7,903 7,345 7,054 6,613 7,536 7,515 6,912 6,647 7,070 6,994 6,564 6,306 7,332 6,978 6,138 6,534 7,160 7,356 6,152 6,340
매출 원가 (1,445) (1,624) (1,569) (1,501) (1,540) (1,581) (1,574) (1,544) (1,552) (2,090) (1,565) (1,442) (1,401) (1,396) (1,395) (1,442) (1,424) (2,627) (1,223) (1,390) (1,361)
제품 판매에 대한 총 이익 5,501 6,279 5,776 5,553 5,073 5,955 5,941 5,368 5,095 4,980 5,429 5,122 4,905 5,936 5,583 4,696 5,110 4,533 6,133 4,762 4,979
로열티, 계약 및 기타 수익 14 22 424 28 54 33 30 42 39 44 57 35 46 57 64 122 56 84 65 65 83
연구 개발 비용 (1,372) (1,583) (1,346) (1,491) (1,379) (1,641) (1,395) (1,351) (1,520) (1,407) (1,457) (1,407) (1,447) (1,548) (1,149) (1,102) (1,178) (2,027) (1,147) (1,134) (1,055)
공정 중 연구 개발 비용 확보 (107) (540) (170) (61) (253) 11 (505) (38) (4,131) (347) (91) (236) (481) (158) (448) (330) (8) (19) (96) (62)
In-process research and development 장애 (400) (190) (1,750) (2,430) (50) (2,700)
판매비, 일반관리비 (1,450) (1,794) (1,357) (1,365) (1,258) (1,906) (1,433) (1,377) (1,375) (1,608) (1,315) (1,849) (1,318) (2,020) (1,213) (1,357) (1,083) (1,650) (1,190) (1,351) (1,055)
영업이익(손실) 2,586 1,984 3,327 2,474 2,237 2,452 888 2,644 (4,322) 1,612 2,623 1,665 1,705 2,267 2,837 2,029 197 940 3,842 2,246 2,890
이자 비용 (240) (254) (256) (254) (260) (248) (238) (237) (254) (252) (232) (230) (230) (226) (229) (242) (238) (238) (250) (256) (257)
그 외의 수입(비용), 순이익 234 347 570 209 (328) (37) 306 (354) 90 293 (73) 153 (175) (10) (176) (284) (111) 57 (154) (173) (369)
소득세 전 소득(손실) 2,580 2,077 3,641 2,429 1,649 2,167 956 2,053 (4,486) 1,653 2,318 1,588 1,300 2,031 2,432 1,503 (152) 759 3,438 1,817 2,264
소득세(비용) 급부금 (559) 106 (589) (469) (334) (384) 297 (439) 316 (236) (146) (549) (315) (398) (646) (368) 164 (383) (852) (300) (542)
순이익(손실) 2,021 2,183 3,052 1,960 1,315 1,783 1,253 1,614 (4,170) 1,417 2,172 1,039 985 1,633 1,786 1,135 12 376 2,586 1,517 1,722
비지배지분으로 인한 순손실 13 8 6 25 7 3 9 7 6 6 5 7
Gilead에 귀속되는 순이익(손실) 2,021 2,183 3,052 1,960 1,315 1,783 1,253 1,614 (4,170) 1,430 2,180 1,045 1,010 1,640 1,789 1,144 19 382 2,592 1,522 1,729

보고서 기준: 10-Q (보고 날짜: 2026-03-31), 10-K (보고 날짜: 2025-12-31), 10-Q (보고 날짜: 2025-09-30), 10-Q (보고 날짜: 2025-06-30), 10-Q (보고 날짜: 2025-03-31), 10-K (보고 날짜: 2024-12-31), 10-Q (보고 날짜: 2024-09-30), 10-Q (보고 날짜: 2024-06-30), 10-Q (보고 날짜: 2024-03-31), 10-K (보고 날짜: 2023-12-31), 10-Q (보고 날짜: 2023-09-30), 10-Q (보고 날짜: 2023-06-30), 10-Q (보고 날짜: 2023-03-31), 10-K (보고 날짜: 2022-12-31), 10-Q (보고 날짜: 2022-09-30), 10-Q (보고 날짜: 2022-06-30), 10-Q (보고 날짜: 2022-03-31), 10-K (보고 날짜: 2021-12-31), 10-Q (보고 날짜: 2021-09-30), 10-Q (보고 날짜: 2021-06-30), 10-Q (보고 날짜: 2021-03-31).